Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: a review of SEER data, 2004-2010

Mary E Charlton; Margaret Peggy Adamo; Leon Sun; Sundeep Deorah

doi:10.1002/cncr.29047

Back

Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: a review of SEER data, 2004-2010

Journal article

Open access

Peer reviewed

Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: a review of SEER data, 2004-2010

Mary E Charlton, Margaret Peggy Adamo, Leon Sun and Sundeep Deorah

Cancer, Vol.120 Suppl 23(S23), pp.3815-3825

12/01/2014

DOI: 10.1002/cncr.29047

PMCID: PMC4267579

PMID: 25412393

Files and links (1)

url

https://doi.org/10.1002/cncr.29047View

Published (Version of record) Open Access

Abstract

Several changes were made to bladder cancer staging guidelines between the 6th and 7th editions of the American Joint Committee on Cancer (AJCC) Staging Manual. Also, Collaborative Stage (CS) Data Collection System version 2 (CSv2) implemented for 2010 Surveillance, Epidemiology, and End Results (SEER) cases involved collection of 3 new site-specific factors (SSFs): World Health Organization/International Society of Urological pathology grade (SSF1), size of metastasis in regional lymph nodes (SSF2), and extranodal extension (SSF3). Our objective was to evaluate these new SSFs to assist researchers in their use/interpretation and to describe data quality issues to be addressed moving forward. Staging trends were assessed for invasive and noninvasive bladder cancer cases from 2004 to 2010. Among 2010 cases, staging was compared using the AJCC 6th and 7th edition guidelines, and evaluation of completeness/quality of the SSFs was performed in relevant subgroups. Age-adjusted incidence rates and proportions of cases by stage remained steady from 2004 to 2010. Changes from the AJCC 6th to 7th editions caused no substantial movement between stages. SSF1 had a known value in 82% of cases, which was higher than the traditional SEER grade/differentiation variable. SSF2 and SSF3 were less complete, with 41% and 37% having known values, respectively, among cases with lymph node involvement (according to CS lymph node variable). SSF1 was more complete and straightforward to interpret than the traditional grade/differentiation variable. SSF2 and SSF3 were less complete, may be associated with data quality issues, and should only be used among cases with known lymph node involvement.

Neoplasms, Glandular and Epithelial - pathology

SEER Program

Lymph Nodes - pathology

Prognosis

Carcinoma, Squamous Cell - pathology

Humans

Male

Neoplasm Staging - trends

Carcinoma, Transitional Cell - pathology

Urinary Bladder Neoplasms - pathology

Female

Retrospective Studies

Cohort Studies

Details

Title: Subtitle: Bladder cancer collaborative stage variables and their data quality, usage, and clinical implications: a review of SEER data, 2004-2010
Creators: Mary E Charlton - Department of Epidemiology & State Health Registry of Iowa, College of Public Health, University of Iowa, Iowa City, Iowa
Margaret Peggy Adamo
Leon Sun
Sundeep Deorah
Resource Type: Journal article
Publication Details: Cancer, Vol.120 Suppl 23(S23), pp.3815-3825
DOI: 10.1002/cncr.29047
PMID: 25412393
PMCID: PMC4267579
NLM abbreviation: Cancer
ISSN: 0008-543X
eISSN: 1097-0142
Publisher: United States
Grant note: HHSN261201000032C / NCI NIH HHS
Language: English
Date published: 12/01/2014
Academic Unit: Health Management and Policy; Epidemiology
Record Identifier: 9983995063702771

Metrics

23 Record Views

58 Times Cited - Web of Science